CSPC Innovation Pharmaceutical (300765) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was ¥471.97 million, down 9.94% year-over-year, with a net loss attributable to shareholders of ¥26.90 million, reversing a profit in the prior year.

• The decline was mainly due to lower caffeine prices impacting functional raw materials and a significant increase in R&D expenses as multiple products entered clinical development.

Financial highlights

• Operating income for Q1 2025 was ¥471.97 million, a 9.94% decrease compared to Q1 2024.

• Net loss attributable to shareholders was ¥26.90 million, compared to a profit of ¥79.06 million in Q1 2024.

• Basic and diluted EPS were both -0.0192, down from 0.0676 year-over-year.

• Cash flow from operating activities improved to -¥86.80 million from -¥975.37 million year-over-year.

• Total assets at quarter-end were ¥6.09 billion, up 1.16% from year-end 2024.

Outlook and guidance

• The company is undergoing regulatory review for a major acquisition of 100% equity in a related biopharmaceutical company, with timing and approval still uncertain.